Developing a new influenza vaccine using plant-derived nanoparticles
MULTIVALENT QS-18 PROTEIN NANOPARTICLES FOR A BROADLY PROTECTIVE INFLUENZA VIRUS VACCINE
This study is testing a new flu vaccine made from a plant ingredient and tiny particles to see if it can help your body fight off different types of the flu better, and it's being done first in animals like mice and ferrets before it can be used in people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10933284 on NIH RePORTER |
What this research studies
This research focuses on creating a novel influenza vaccine that utilizes QS-18, a plant-derived saponin, combined with advanced nanoliposome technology. The approach aims to enhance the vaccine's effectiveness by improving the immune response through the use of specific influenza virus components. The study will involve testing the vaccine's safety and efficacy in animal models, including mice and ferrets, to gather essential data for future clinical applications. By exploring the potential of this innovative vaccine formulation, the research seeks to provide a broader protective response against various strains of the influenza virus.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for influenza, such as the elderly or those with compromised immune systems.
Not a fit: Patients who are not at risk for influenza or those who have already received a flu vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and broadly protective influenza vaccine, potentially reducing the incidence of flu and its complications.
How similar studies have performed: Other research has shown promise in using plant-derived adjuvants and nanotechnology for vaccine development, indicating a potential for success in this novel approach.
Where this research is happening
Buffalo, United States
- Pop Biotechnologies, INC — Buffalo, United States (Active)
Researchers
- Principal investigator: Singleton, Kentner — Pop Biotechnologies, INC
- Study coordinator: Singleton, Kentner
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.